Allstocks.com's Bulletin Board Post A Reply
my profile login | register | search | faq | forum home

» Allstocks.com's Bulletin Board » FOREX Market » HIV Drug May Be Widely Available after Approval » Post A Reply

Post A Reply
Login Name:
Password:
Message Icon: Icon 1     Icon 2     Icon 3     Icon 4     Icon 5     Icon 6     Icon 7    
Icon 8     Icon 9     Icon 10     Icon 11     Icon 12     Icon 13     Icon 14    
Message:

HTML is enabled.
UBB Code™ is enabled.

 

Instant Graemlins Instant UBB Code™
Smile   Frown   Embarrassed   Big Grin   Wink   Razz  
Cool   Roll Eyes   Mad   Eek!   Confused   BadOne  
Good Luck   More Crap   Wall Bang   Were Up   Were Down    
Insert URL Hyperlink - UBB Code™   Insert Email Address - UBB Code™
Bold - UBB Code™   Italics - UBB Code™
Quote - UBB Code™   Code Tag - UBB Code™
List Start - UBB Code™   List Item - UBB Code™
List End - UBB Code™   Image - UBB Code™

What is UBB Code™?
Options


Disable Graemlins in this post.


 


T O P I C     R E V I E W
biotechguy0331  - posted
http://www.NutraPharma.com

Nutra Pharma Reports ReceptoPharm Assays Prove That Experimental HIV Drug May Be Widely Available after Approval
--------------------------------------------------------------------------------

1-Sep-2004

BOYNTON BEACH, Fla.--(BUSINESS WIRE)--Sept. 1, 2004--Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology holding company that owns rights to patents and intellectual property related to the development of drugs for HIV and Multiple Sclerosis, has announced today that its minority-owned holding, ReceptoPharm, Inc., has discovered the potential for widely available cobra venoms as a raw material in the development of a treatment for HIV and possibly AIDS. This is a significant discovery as cobras are indigenous where HIV infection is rampant. Cobra venom from different geographical locations has been assayed for effectiveness in inhibiting HIV replication. Venoms from cobras found in Africa and Asia have demonstrated antiviral activity.
"This permits the use of diverse venom sources to produce the drug in a cost-effective way and meet the requirements of the millions in need of treatment," commented Paul Reid, PhD, CEO of ReceptoPharm. "The production of cobra venom for use in antisera manufacturing is well established and could be scaled-up to meet the demands for anti-retroviral therapy. Tens if not hundreds of kilograms of venoms are produced globally and the Company believes that one kilogram could provide as many as one million doses. Our recent efforts in cloning one of the active components should increase drug supply," he concluded.

The key now to a promising new drug is its ability to block emerging drug-resistant HIV strains. The Company is examining this aspect in independent laboratories and feels confident that this should not be a problem. Preliminary research suggests the anti-viral mechanism is independent of current treatment methods. The venom's complexity should also make it more resilient to the development of resistant viral strains.

"The drug already has a well established history in humans so we believe that clinical studies should commence quickly," stated Rik Deitsch, Nutra Pharma's CEO. "By showing that there is a ready supply of natural raw material, ReceptoPharm may be able to quickly supply the drug to patients in the geographic areas most desperate for cost-effective treatment," he added.

ReceptoPharm recently moved into a larger facility and expects to move quickly into GMP production. The Company has near-term requirements for drug supplies to meet clinical trial demands and non-clinical studies. Raw material suppliers in the U.S. have been validated and sufficient venom supplies are available for the current clinical program and early commercialization.

About Nutra Pharma Corp.

Nutra Pharma Corp. is a biotechnology holding company that owns rights to patents and intellectual property related to the development of drugs for HIV and Multiple Sclerosis ("MS"). The Company's minority-owned holding, ReceptoPharm, Inc., is developing these technologies. The Company's majority-owned subsidiary, Infectech, Inc., is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma will continue to identify and acquire intellectual property and companies in the biotechnology arena. http://www.nutrapharma.com

About ReceptoPharm

ReceptoPharm, Inc. is a bio-pharmaceutical company developing proprietary therapeutic proteins for the treatment of several chronic, life-threatening viral, auto-immune and neuro-degenerative disorders, specifically including Rabies, HIV, and Myasthenia gravis (MG).

Safe Harbor under the Private Securities Litigation Reform Act of 1995: The statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including, but not limited to, risks associated with the uncertainty of future financial results, regulatory approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties as may be detailed in the Company's filings with the Securities and Exchange Commission. Nothing in this press release shall be construed as an offer to buy or sell any securities herein.



 

ChrisNC  - posted
Nice find Ill be watching it

------------------
Einsteins 8th wonder of the world was the power of multiplication-Buffology lives on in penny land
 

jimbo  - posted
Shot up today... news was last week. What's up?

NUTRA PHARM CP (OTC BB: NPHC.OB)
Last Trade: 0.33
Trade Time: Oct 12
Change: 0.09 (37.50%)
Prev Close: 0.24
Open: 0.23
Bid: 0.32 x 5000
Ask: 0.34 x 5000
1y Target Est: N/A

Day's Range: 0.23 - 0.34
52wk Range: 0.22 - 0.95
Volume: 226,051
Avg Vol (3m): 62,227
Market Cap: 16.73M
P/E (ttm): N/A
EPS (ttm): -0.092
Div & Yield: N/A (N/A)

Any Guesses how high it will go?

------------------

Jimbo...
 

ChrisNC  - posted
you da man

------------------
Einsteins 8th wonder of the world was the power of multiplication-Buffology lives on in penny land
 

jimbo  - posted
WOW OH WOW!!!

Did anyone see this???
NUTRA PHARM CP (OTC BB: NPHC.OB) Delayed quote data by Reuters

Last Trade: 0.53
Trade Time: Oct 13
Change: 0.20 (60.61%)
Prev Close: 0.33
Open: 0.32
Bid: 0.53 x 2500
Ask: 0.55 x 2500
1y Target Est: N/A

Day's Range: 0.295 - 0.635
52wk Range: 0.22 - 0.95
Volume: 554,085
Avg Vol (3m): 65,409
Market Cap: 26.87M
P/E (ttm): N/A
EPS (ttm): -0.092
Div & Yield: N/A (N/A)

I repeat: Day's Range: 0.295 - 0.635

Now that is what I am talking about.
This was a good call biotechguy. I hope everyone got in at a good price and rode it up.


------------------

Jimbo...
 

jimbo  - posted
This was your start from $1k to $100k - double-runee (da bull roo knee) I just made up a word. LOL

------------------

Jimbo...
 

thebigpoppa  - posted
this is really great news.
some of the major problems with companies that get an hiv drug is not having the ability to produce enough therefore limiting sales.
quote:
Originally posted by biotechguy0331:
http://www.NutraPharma.com

Nutra Pharma Reports ReceptoPharm Assays Prove That Experimental HIV Drug May Be Widely Available after Approval



 

thebigpoppa  - posted
also had a chance to listen to the ceocast.com interview with nutrapharma ceo. i encourage all to check it out.

quote:
Originally posted by thebigpoppa:
this is really great news.
some of the major problems with companies that get an hiv drug is not having the ability to produce enough therefore limiting sales.


 

thebigpoppa  - posted
nutrapharma expects to have results from hiv study around end of forst qtr 2005.
quote:
Originally posted by thebigpoppa:
also had a chance to listen to the ceocast.com interview with nutrapharma ceo. i encourage all to check it out.



 

tfct24  - posted
quote:
Originally posted by thebigpoppa:
nutrapharma expects to have results from hiv study around end of forst qtr 2005.

I AM highly confused, I have been watching this stock for a week now and the VOLUME TODAY WAS 500 SHARES. I just dont understand the sex appeal of this stock, no one knows about it and you guys say it could go up to $20.00, please explain?
 

gatorbowl  - posted
Does anybody know what is going on with the stock NPHC? This stock has tanked alot this last year. thebigpoppa was wrong on everything he said and now we haven't heard from him in 1 year. If anybody has an opinion on this company, please share it with the rest of us.
 
gatorbowl  - posted
This message is for tfct24 or anyone who has been watching the stock NPHC. Does anyone think this company has potential? There website is www.nutrapharma.com According to there news they have and HIV drug, MS drug, and a AMN drug that may work. But the problem is they have been saying for the last 2 years that there going to begin human trials and they haven't began anything. It seems very misleading to me, but what due I know. The only thinh I know is the stock is 20 cents per share and they have no trading volume. Please give me your thoughts if possible.
 
gatorbowl  - posted
I have did some research on Nutra Pharma Corporation. I think it is only a matter of time before this company moves to the next level. it looks like by years end or first part of 2006 they will access to roughly $10MM. If this drug works like the beginning tests have stated on the past news and continues to show positive results, this could be a huge gain from there current price.
 
biotechguy0331  - posted
Hey all -- NPHC has gone up and way down since I originally posted...I'm still really high on this company because its pipeline is so good. The deal they signed with SBI will put them on the map. I blieve they are just waiting for the shares to be registered with the SEC...between SBI and this other company in China (you know - the one that is being paid in $0.70 warrants!!), Nutra Pharma shares only have one way to go -- and that is UP! I believe they were waiting for the additional capital to begin the phase III trials -- someone else might know the answer to this, but don't most of these companies have the big pharma companies come in to license at Phase III? Good luck to all -- FYI, I avg'd down when the stock was low.
 
biotechguy0331  - posted
Anyone else following this company still? I always check out their website to see what information they posted...it doesnt make any sense why the company is so undervalued...any thoughts?
 
gatorbowl  - posted
After doing my homework on Nutra Pharma Corporation I have found the following. They have diluted there stock alot over the last 2 years. They have to raise money on an ongoing basis. This drug has been around for 15 years and has yet to make it to the market. I think it could have huge potential but looks like a long shot when you look at the overall picture. The stock has been trading at all time lows between 11-15 cents.
 
biotechguy0331  - posted
Just pulled this -- Nutra Pharma Corp. (OTC BB:NPHC.OB), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, has announced that it has been accepted into the Stop TB Partnership. Designer Diagnostics, a wholly owned subsidiary of Nutra Pharma has also been accepted into the organization.

full press release is on their site (http://www.nutrapharma.com) -- this helps legitimize the company...
 
biotechguy0331  - posted
Nutra Pharma Announces Approval to Start Late Phase II Human Trials in England

More details at http://www.NutraPharma.com
 
biotechguy0331  - posted
Nutra Pharma should see revenues this quarter! YAY!!!
 



Contact Us | Allstocks.com Message Board Home

© 1997 - 2021 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share